[Effect of cerebrolysin on remyelination processes in multiple sclerosis patients in stage of relapse regression].

Khabirov FA, Khaybullin TI, Granatov EV, Shakirzianova SR

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova1 Jan 2016Cited by 3 (Europe PMC)

PMID28139626DOI10.17116/jnevro201611612148-53PepBankPUB-28139626

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialOther
In multiple sclerosis, 17 cerebrolysin patients and 18 saline patients completed the full treatment course.
In plain wordsIn multiple sclerosis, 17 cerebrolysin patients and 18 saline patients completed treatment.
Peptide
Cerebrolysin
Outcome
Direction not reportedTreatment completion
Study
n = 40
Comparator
Saline
Outcome group
Adverse events · Whole body
Studied dose
20 mlAs given in this study (human).
Measurements
Treatment completion count
17 patients
Cerebrolysin (G1)
Treatment completion proportion
85%
Cerebrolysin (G1)
Treatment completion count
18 patients
Saline (G2)
Treatment completion proportion
90%
Saline (G2)
Source sentences
Summary
17 patients (85%) in G1 and 18 patients (90%) in G2 completed a full course of treatment.
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962601
02HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, EDSS improved in both groups, without a significant difference between cerebrolysin and saline.
In plain wordsIn multiple sclerosis, disability scores improved in both groups, with no significant difference between cerebrolysin and saline.
Peptide
Cerebrolysin
Outcome
No significant changeEDSS improvement
Study
n = 40
Comparator
Saline
Outcome group
Overall treatment effect · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
EDSS
2 points
Cerebrolysin (G1) after treatment
EDSS bracketed interval (type not stated)
1.75 to 2.5 points
Cerebrolysin (G1) after treatment
EDSS
2.5 points
Saline (G2) after treatment
EDSS bracketed interval (type not stated)
1.75 to 2.5 points
Saline (G2) after treatment
P value for EDSS intergroup difference
0.665
Cerebrolysin (G1) versus saline (G2)
EDSS
3.5 points
Cerebrolysin (G1) in relapse stage before treatment
EDSS bracketed interval (type not stated)
2 to 4.5 points
Cerebrolysin (G1) in relapse stage before treatment
EDSS
3 points
Saline (G2) in relapse stage before treatment
1 more measurement in the study.
Source sentences
Summary
In both groups showed significant regression estimation EDSS (2.0 [1.75; 2.5] vs. 2.5 [1.75; 2.5]), while significant intergroup differences were not found (p=0.665).
4 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Summary · context
the EDSS in relapse stage - 3.5 [2.0; 4.5] points.
Summary · context
the EDSS in relapse stage - 3.0 [1.5; 4.5] points.
Report a problemFND-2813962602
03HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, cerebrolysin produced greater MSFC improvement than saline.
In plain wordsIn multiple sclerosis, cerebrolysin improved MSFC performance more than saline.
Peptide
Cerebrolysin
Outcome
IncreaseMSFC performance
Study
n = 40
Comparator
Saline
Outcome group
Exercise and physical function · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
P value for MSFC improvement
0.038
Cerebrolysin (G1) versus saline (G2)
Source sentences
Summary
In G1 was noted more pronounced dynamics of performance improved in testing MSFC and SDMT (p=0.038 and p=0.026, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962603
04HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, cerebrolysin produced greater SDMT improvement than saline.
In plain wordsIn multiple sclerosis, cerebrolysin improved SDMT performance more than saline.
Peptide
Cerebrolysin
Outcome
IncreaseSDMT performance
Study
n = 40
Comparator
Saline
Outcome group
Cognition and memory · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
P value for SDMT improvement
0.026
Cerebrolysin (G1) versus saline (G2)
Source sentences
Summary
In G1 was noted more pronounced dynamics of performance improved in testing MSFC and SDMT (p=0.038 and p=0.026, respectively).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962604
05HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, VCAT improvement did not differ significantly between cerebrolysin and saline.
In plain wordsIn multiple sclerosis, VCAT improvement did not differ significantly between cerebrolysin and saline.
Peptide
Cerebrolysin
Outcome
No significant changeVCAT improvement
Study
n = 40
Comparator
Saline
Outcome group
Vision and retina · Eye
Studied dose
20 mlAs given in this study (human).
Measurements
P value for VCAT improvement
0.658
Cerebrolysin (G1) versus saline (G2)
Source sentences
Summary
Significant intergroup differences in the dynamics of improvement VCAT values were not found (p=0.658).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962605
06HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, cerebrolysin produced greater regression of CNE total variance than saline, although abnormalities usually persisted.
In plain wordsIn multiple sclerosis, cerebrolysin reduced neurophysiological abnormalities more than saline, but abnormalities usually remained.
Peptide
Cerebrolysin
Outcome
IncreaseCNE total variance regression
Study
n = 40
Comparator
Saline
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
CNE total variance regression
70.59%
Cerebrolysin (G1)
CNE total variance regression
27.78%
Saline (G2)
P value for CNE total variance regression
0.028
Cerebrolysin (G1) versus saline (G2)
Source sentences
Summary
Also in G1 was revealed greater regression of total variance in the CNE than G2 (70.59% vs. 27.78%, p=0.028), while in almost all cases the previously identified neurophysiological abnormalities are not completely regressed.
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962606
07HumanRandomized controlled trialEfficacy outcome
In multiple sclerosis, progressive CNE deterioration showed a nonsignificant lower frequency with cerebrolysin than saline.
In plain wordsIn multiple sclerosis, progressive neurophysiological deterioration was numerically lower with cerebrolysin than saline, without statistical significance.
Peptide
Cerebrolysin
Outcome
No significant changeProgressive CNE deterioration
Study
n = 40
Comparator
Saline
Outcome group
Neuroprotection · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
Progressive CNE deterioration
10%
Cerebrolysin (G1)
Progressive CNE deterioration
30%
Saline (G2)
P value for Progressive CNE deterioration
0.228
Cerebrolysin (G1) versus saline (G2)
Source sentences
Summary
In addition to G1 was marked a tendency to reduce of progressive deterioration of CNE indicators (10% vs. 30%; p=0.228).
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962607
08HumanRandomized controlled trialEfficacy outcome
In four multiple sclerosis patients receiving cerebrolysin, MRI G+L counts changed from 14 before treatment to 12 afterward.
In plain wordsIn four multiple sclerosis patients receiving cerebrolysin, MRI lesion counts decreased from 14 to 12.
Peptide
Cerebrolysin
Outcome
DecreaseGadolinium-positive lesions
Study
n = 4
Outcome group
Inflammation markers · Nervous system and cognition
Studied dose
20 mlAs given in this study (human).
Measurements
Gadolinium-positive lesion count
14 lesions
Four Cerebrolysin patients before treatment
Gadolinium-positive lesion count
12 lesions
Four Cerebrolysin patients after treatment
Source sentences
Summary
On MRI cerebrolysin treatment was not associated with an increase of G+L (G+L number before treatment in 4 patients - 14, after treatment - 12)
2 context sentences(design, population, supporting numbers)
Summary · context
The study involved 40 patients with remitting MS (McDonald criteria 2010) in stage of MS relapse regression after pulse therapy with methylprednisolone 1000 mg/day 5.
Summary · context
Patients randomized into 2 groups: group 1 (G1, n=20) received cerebrolysin 20 ml per 200 ml of 0.9% NaCl solution 1 times per day 10; Group 2 (G2, n=20) - only 200 ml 0.9% NaCl solution on analogical scheme.
Report a problemFND-2813962608

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
14 Oct 2026, 05:02 UTC
Study results updated
Version 1
14 Oct 2026, 01:46 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.